Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Regorafenib for post–PD-1 advanced hepatocellular carcinoma
ChiCTR2500111736Phase 4Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab and regorafenib in hepatocellular carcinoma (HCC), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Objective response rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
toripalimabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500111736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111736.